Applied Therapeutics
$0.1
67
+$0+0.19% Monday 21:00
Statistics
Day High
0.11
Day Low
0.1
52W High
1.5
52W Low
0.09
Volume
2,690,459
Avg. Volume
16,032,278
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
13MarExpected
Expected EPS
-0.116667
Actual EPS
N/A
Financials
-23,214.07%Profit Margin
Unprofitable910,000Revenue
-211.25MNet Income
Analyst Ratings
$1.00Average Price Target
The highest estimate is 1.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 0%
Hold 100%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow APLT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Biogen
BIIB
Mkt Cap22.63B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
AMGEN
AMGN
Mkt Cap160.66B
Gilead Sciences
GILD
Mkt Cap148.78B
Novo Nordisk
NVO
Mkt Cap217.54B
Pfizer
PFE
Mkt Cap140.15B
About
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Show more...
CEO
Mr. John H. Johnson
Employees
35
Country
US
ISIN
US03828A1016
Listings
0 Comments
Share your thoughts
FAQ
What is Applied Therapeutics stock price today?▼
The current price of APLT is $0.1 USD — it has increased by +0.19% in the past 24 hours. Watch Applied Therapeutics stock price performance more closely on the chart.
What is Applied Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Applied Therapeutics stocks are traded under the ticker APLT.
Is Applied Therapeutics stock price growing?▼
APLT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Applied Therapeutics has showed a -77.61% decrease.
What is Applied Therapeutics revenue for the last year?▼
Applied Therapeutics revenue for the last year amounts to 910,000 USD.
What is Applied Therapeutics net income for the last year?▼
APLT net income for the last year is -211.25M USD.
How many employees does Applied Therapeutics have?▼
As of April 01, 2026, the company has 35 employees.
In which sector is Applied Therapeutics located?▼
Applied Therapeutics operates in the Health Care sector.
When did Applied Therapeutics complete a stock split?▼
Applied Therapeutics has not had any recent stock splits.
Where is Applied Therapeutics headquartered?▼
Applied Therapeutics is headquartered in New York, US.